PL2179737T3 - Sposób do modulowania wrażliwości na steroidy - Google Patents

Sposób do modulowania wrażliwości na steroidy

Info

Publication number
PL2179737T3
PL2179737T3 PL09167538T PL09167538T PL2179737T3 PL 2179737 T3 PL2179737 T3 PL 2179737T3 PL 09167538 T PL09167538 T PL 09167538T PL 09167538 T PL09167538 T PL 09167538T PL 2179737 T3 PL2179737 T3 PL 2179737T3
Authority
PL
Poland
Prior art keywords
steroids
oligonucleotide
responding
modulating responsiveness
steroid
Prior art date
Application number
PL09167538T
Other languages
English (en)
Inventor
Ann-Kristin Spiik
Robert Löfberg
Lisa Charlotta Bandholtz
Stein Oliver Von
Arezou Zargari
Original Assignee
Index Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Index Pharmaceuticals Ab filed Critical Index Pharmaceuticals Ab
Publication of PL2179737T3 publication Critical patent/PL2179737T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL09167538T 2005-07-01 2006-06-30 Sposób do modulowania wrażliwości na steroidy PL2179737T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69605005P 2005-07-01 2005-07-01
EP09167538.9A EP2179737B1 (en) 2005-07-01 2006-06-30 Modulating responsiveness to steroids
EP06748071A EP1904077B1 (en) 2005-07-01 2006-06-30 Modulating responsiveness to steroids

Publications (1)

Publication Number Publication Date
PL2179737T3 true PL2179737T3 (pl) 2014-01-31

Family

ID=37604740

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09167538T PL2179737T3 (pl) 2005-07-01 2006-06-30 Sposób do modulowania wrażliwości na steroidy

Country Status (11)

Country Link
US (2) US8148341B2 (pl)
EP (2) EP2179737B1 (pl)
JP (2) JP5208734B2 (pl)
AT (1) ATE439135T1 (pl)
DE (1) DE602006008473D1 (pl)
DK (1) DK2179737T3 (pl)
ES (2) ES2330884T3 (pl)
PL (1) PL2179737T3 (pl)
PT (1) PT2179737E (pl)
SI (1) SI2179737T1 (pl)
WO (1) WO2007004979A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2179737E (pt) * 2005-07-01 2013-12-05 Index Pharmaceuticals Ab Método para modular a capacidade de resposta aos esteróides
SI2380584T1 (sl) * 2005-07-01 2014-04-30 Index Pharmaceuticals Ab Imunostimulatorni postopek
AU2006306805A1 (en) * 2005-10-28 2007-05-03 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
EP2207555B1 (en) * 2007-10-05 2013-07-24 InDex Pharmaceuticals AB Oligonucleotides for the treatment or alleviation of edema
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
NZ584793A (en) 2007-10-26 2012-05-25 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US20110182880A1 (en) * 2008-06-18 2011-07-28 Oliver Von Stein Combination Therapies Against Cancer
ES2560782T3 (es) 2008-11-04 2016-02-22 Index Pharmaceuticals Ab Compuestos y métodos para el tratamiento de enfermedades inflamatorias del SNC
WO2012084991A1 (en) * 2010-12-21 2012-06-28 Index Pharmaceuticals Ab Biologically active oligonucleotides capable of modulating the immune system ii
EP2596806A1 (en) 2011-11-25 2013-05-29 Index Pharmaceuticals AB Method for prevention of colectomy
CA2862628C (en) 2012-01-27 2021-08-24 Prosensa Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
GB201707501D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy 2
GB201707503D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New Therapy 3

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
TW244371B (pl) 1992-07-23 1995-04-01 Tri Clover Inc
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
CA2105595A1 (en) 1992-09-23 1994-03-24 Ramaswamy Narayanan Antisense polynucleotides
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
CA2244946C (en) 1996-01-30 2010-04-13 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
US20030078223A1 (en) 1996-01-30 2003-04-24 Eyal Raz Compositions and methods for modulating an immune response
SE9602300D0 (sv) * 1996-06-11 1996-06-11 Karolinska Innovations Ab New composition and methods
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP1077708A1 (en) 1998-05-06 2001-02-28 University Of Iowa Research Foundation Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
AU760795B2 (en) 1998-05-14 2003-05-22 Coley Pharmaceutical Gmbh Methods for regulating hematopoiesis using CpG-oligonucleotides
DK1077722T3 (da) 1998-05-22 2006-11-27 Ottawa Health Research Inst Fremgangsmåder og produkter til induktion af mukosaimmunitet
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
JP4663047B2 (ja) * 1998-07-13 2011-03-30 株式会社半導体エネルギー研究所 レーザー照射装置及び半導体装置の作製方法
JP2002521489A (ja) 1998-07-27 2002-07-16 ユニバーシティ オブ アイオワ リサーチ ファウンデーション ＣｐＧオリゴヌクレオチドの立体異性体および関連する方法
WO2001022972A2 (en) 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
EP1688147A1 (en) 1999-09-27 2006-08-09 Coley Pharmaceutical Group, Inc. Methods Related to Immunostimulatory Nucleic Acid-Induced Interferon
IL148844A0 (en) 1999-09-27 2002-09-12 Coley Pharm Group Inc Methods related to immunostimulatory nucleic acid-induced interferon
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US20040131628A1 (en) 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US20020107212A1 (en) 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US6649341B1 (en) 2000-04-19 2003-11-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Human glucocorticoid receptor 1A promoter and splice variants
EP1296714B1 (en) 2000-06-22 2009-08-26 University Of Iowa Research Foundation Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
US20020198165A1 (en) 2000-08-01 2002-12-26 Bratzler Robert L. Nucleic acids for the prevention and treatment of gastric ulcers
EP1366077B1 (en) 2000-09-15 2011-05-25 Coley Pharmaceutical GmbH PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
US6294382B1 (en) 2000-11-27 2001-09-25 Isis Pharmaceuticals, Inc. Antisense modulation of SRC-1 expression
AU2002248185A1 (en) 2000-12-14 2002-07-16 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
JP2002257827A (ja) 2001-03-01 2002-09-11 Jenokkusu Soyaku Kenkyusho:Kk ステロイド応答性の検査方法
US20030050268A1 (en) 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
AU2002256359A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
JP4397571B2 (ja) * 2001-09-25 2010-01-13 株式会社半導体エネルギー研究所 レーザ照射方法およびレーザ照射装置、並びに半導体装置の作製方法
WO2003031573A2 (en) 2001-10-05 2003-04-17 Coley Pharmaceutical Gmbh Toll-like receptor 3 signaling agonists and antagonists
KR20050048539A (ko) 2001-10-06 2005-05-24 메리얼엘엘씨 ＣｐＧ 제제 및 관련된 방법
US7105048B2 (en) * 2001-11-30 2006-09-12 Semiconductor Energy Laboratory Co., Ltd. Laser irradiation apparatus
JP3934536B2 (ja) * 2001-11-30 2007-06-20 株式会社半導体エネルギー研究所 レーザ照射装置およびレーザ照射方法、並びに半導体装置の作製方法
AU2003203079B9 (en) 2002-02-04 2009-01-15 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
NZ535952A (en) 2002-04-04 2009-01-31 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
US6977775B2 (en) * 2002-05-17 2005-12-20 Sharp Kabushiki Kaisha Method and apparatus for crystallizing semiconductor with laser beams
JP4474108B2 (ja) * 2002-09-02 2010-06-02 株式会社 日立ディスプレイズ 表示装置とその製造方法および製造装置
US20060257851A1 (en) 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
DK1992635T3 (da) 2002-12-23 2012-03-05 Dynavax Tech Corp Oligonukleotider med immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse
US7625872B2 (en) 2002-12-23 2009-12-01 Dynavax Technologies Corporation Branched immunomodulatory compounds and methods of using the same
JP4726630B2 (ja) 2003-01-16 2011-07-20 イデラ ファーマシューティカルズ インコーポレイテッド 修飾された免疫賦活性ジヌクレオチドを用いることによるオリゴヌクレオチドに基づく化合物の免疫賦活特性の調節
CN101675993A (zh) 2003-03-26 2010-03-24 赛托斯生物技术公司 Melan-a肽类似物-病毒样颗粒偶联物
EP1608403A2 (en) * 2003-04-02 2005-12-28 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
KR20060012622A (ko) 2003-05-16 2006-02-08 하이브리돈, 인코포레이티드 화학요법제와 함께 이뮤노머를 사용하는 상승적 암 치료방법
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
US20050158325A1 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Immunomodulatory combinations
JP2007523173A (ja) 2004-02-20 2007-08-16 イデラ ファーマシューティカルズ インコーポレイテッド 修飾免疫調節オリゴヌクレオチドにより誘導された強力な粘膜免疫応答
EP1716234B1 (de) 2004-02-20 2013-10-02 Mologen AG Substituiertes, nicht-kodierendes nukleinsäuremolekül zur therapeutischen und prophylaktischen immunstimulation in menschen und höheren tieren
SE0400399D0 (sv) 2004-02-20 2004-02-20 Index Pharmaceuticals Ab Methods and compositions for the treatment or prevention of secondary ischemic injury
BRPI0512110A (pt) 2004-06-15 2007-10-23 Idera Pharmaceutical Inc multìmeros de oligonucleotìdeos imunoestimulatórios
JP5072197B2 (ja) * 2004-06-18 2012-11-14 株式会社半導体エネルギー研究所 レーザ照射装置およびレーザ照射方法
WO2006015560A1 (de) 2004-08-09 2006-02-16 Mologen Ag Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
PL1794174T3 (pl) 2004-09-01 2012-11-30 Dynavax Tech Corp Sposoby i kompozycje do hamowania wrodzonych odpowiedzi immunologicznych i autoodporności
EP1874325A2 (en) * 2005-04-08 2008-01-09 Coley Pharmaceutical Group, Inc. Methods for treating infectious disease exacerbated asthma
PT2179737E (pt) * 2005-07-01 2013-12-05 Index Pharmaceuticals Ab Método para modular a capacidade de resposta aos esteróides
SI2380584T1 (sl) * 2005-07-01 2014-04-30 Index Pharmaceuticals Ab Imunostimulatorni postopek

Also Published As

Publication number Publication date
JP2012193192A (ja) 2012-10-11
US8569257B2 (en) 2013-10-29
US20120172420A1 (en) 2012-07-05
EP1904077A1 (en) 2008-04-02
ES2435531T3 (es) 2013-12-20
JP5886699B2 (ja) 2016-03-16
ATE439135T1 (de) 2009-08-15
SI2179737T1 (sl) 2014-02-28
JP2008544984A (ja) 2008-12-11
EP1904077B1 (en) 2009-08-12
DK2179737T3 (da) 2013-11-11
EP2179737A3 (en) 2010-08-25
US20080318885A1 (en) 2008-12-25
EP2179737A2 (en) 2010-04-28
WO2007004979A1 (en) 2007-01-11
PT2179737E (pt) 2013-12-05
ES2330884T3 (es) 2009-12-16
US8148341B2 (en) 2012-04-03
JP5208734B2 (ja) 2013-06-12
DE602006008473D1 (de) 2009-09-24
EP2179737B1 (en) 2013-08-14

Similar Documents

Publication Publication Date Title
CY1114965T1 (el) Cpg ολιγονουκλεοτιδια χρησιμοποιουμενα για ενισχυση της δραστικοτητας στεροειδων σε εναν εξαρτημενο απο στεροειδη ασθενη
SI2179737T1 (sl) Modulacija reakcije na stereoide
MX2009000385A (es) Acil-anilidas sustituidas y metodos de uso de las mismas.
HUE044182T2 (hu) Génterápia amiotrófiás laterális szklerózis és más gerincvelõ-rendellenességek kezelésére
IL201479A (en) Use of tapentadol for the preparation of pain medication
BRPI0607002A2 (pt) aptámeros terapêuticos úteis no tratamento de desordens relacionadas a complemento
NO20081884L (no) Modulasjon av glukagonreseptorekspresjon
CL2008001721A1 (es) Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales.
BRPI0512944A (pt) agentes terapêuticos para o tratamento de patologias relacionadas com hmgb1
PT2056805E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular
IL189104A (en) Pharmaceutical preparation containing lasalazide or sodium balasalazide for use in the treatment of gastrointestinal disorders.
UA90467C2 (ru) Применение пептидных соединений для лечения боли при болезненой диабетической невропатии
WO2007135505A8 (en) Veterinary pharmaceutical compositions for the treatment of pain and inflammation
BR112014009322A8 (pt) inibidor de catecol-o-metiltransferase (comt), combinação do mesmo com um agente terapêutico adicional e agente terapêutico
PT1864668E (pt) Utilização de pró-fármacos para administração ocular intravítrea
NO20055098D0 (no) Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser
IL198202A0 (en) Peptide-cytotoxic conjugates
PL1612210T3 (pl) Nowe analogi nitrobenzylotioinozyny
HUP0600489A2 (en) Use of echinacea or preparations made thereof for the manufacture of pharmaceutical compositions for the treatment of anxiety
PL1948194T3 (pl) Zastosowanie kwasu klodronowego do leczenia zespołu trzeszczkowego
FI20080543A0 (fi) Kauha
ES1060066Y (es) Camilla para tratamientos terapeuticos.